Homepage
Author:
NurExone Biologic Inc
Posted Date:
May 14, 2026
NurExone Advances to Stage 2 of EU-Backed EIT Health Catapult Programme 2026
NurExone Biologic Inc
May 14, 2026
Australian Patent Granted to NurExone Covering Stem Cell-Derived Exosome Production
NurExone Biologic Inc
April 27, 2026
NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update
NurExone Biologic Inc
April 16, 2026
NurExone Biologic’s U.S. Subsidiary Exo-Top and Florida-Based BioXtek Sign Strategic LOI for Exosome Manufacturing and Commercialization
NurExone Biologic Inc
April 7, 2026
NurExone Receives First Place in Healthcare at BOLD Awards VII and Engages Investor Brand Network to Support Awareness Strategy
NurExone Biologic Inc
April 1, 2026
NurExone Announces Corporate Updates
NurExone Biologic Inc
March 11, 2026
NurExone to Showcase Its Regenerative Medicine Platform at NANO.IL.2026 and Advanced Therapies Congress in March 2026 and Provides Corporate Update
NurExone Biologic Inc
February 27, 2026
NurExone Appoints Eyal Gabbai to Board, Adding Large-Scale Healthcare System and Capital Markets Expertise
NurExone Biologic Inc
January 30, 2026
